This site has limited support for your browser. We recommend switching to Edge, Chrome, Safari, or Firefox.

Free US shipping on all orders

The Science

01

Who we are

We're Mikra — a group of world-renowned scientists, doctors, Olympic medalists, parents and chronic disease survivors from around the globe with one mission: engineer cellular therapeutics that increase the period of life spent in good health.

We are pushing biosciences beyond the expected and comfortable, by taking a pharmaceutical approach to supplements with the goal of increasing your healthspan.

02

Form follows function

We don't focus on fancy packaging, fairy dusting or trendy molecules. Instead, we focus on utilizing evidence-based bioactive compounds with a pharmaceutical-grade delivery system.

Our science isn't static — there are 91,472 PubMed publications around our bioactive compounds and delivery technology (and counting).

We've got it down to a science.
03

Consistent & effective dosage

Bioactive Validation

Our science, research and development partners sift through extensive clinical data made available to us through academic institutions to understand the optimal dosage of bioactive compounds required to impact cellular health.


Evidence-Backed Dosage

We consistently deliver bioactive compounds at a dosage at or above the label claim. The compounds are then preserved throughout the manufacturing process and shipping environments.


04

Review the facts

We believe nutraceuticals that work like pharmaceuticals are the future of supplements.

Our products go through a rigorous research and development process to ensure your body receives evidence-backed ingredients that actually work.

Brain & nervous system health Study Type
Nakano M., et al. 2009 Clinical, randomized, double-blind
Nakano M., et al. 2015 Clinical, randomized, double-blind
Itoh Y., Hine K., et al. 2016 Clinical, randomized, double-blind
Chen, J.J., Thiyagarajah, M., et al. 2022 Meta-analysis
Block, K.I., Koch, A.C., et al. 2008 Systematic review
Hajjar I., Hayek SS., et al. 2018 Longitudinal cohort study
Ansari MA., Scheff SW. 2010 Clinical trial
Bermejo P., Martín-Aragón S., et al. 2008 Clinical trial
Nakano M., Yamamoto T., et al. 2012 Clinical, open label design
Mandal PK., Tripathi M., Sugunan S., 2012 Clinical trial
Duffy SL., Lagopoulos J., et al. 2013 Clinical trial
Shukitt-Hale B., Smith DE., et al. 1999 Preclinical study
Ohwada K., Takeda H., et al. 2008 In vivo, preclinical study
Takatsu H., Owada K., et al. 2009 In vivo, preclinical study
Yamaguchi K., Sasano A., et al. 1993 In vitro and in vivo, preclinical study
Murase K., Hattori A., et al. 1993 In vitro, preclinical study
Hara H., Hiramatsu H., Adachi T., 2007 In vitro, preclinical study
Cellular function & healthy aging Study Type
Sangsefidi, Z. S., Yaghoubi, F., et al. 2020 Systematic review, meta-analysis
Akbari A., Mobini G. R., et al. 2020 Systematic review, meta-analysis
Hajiluian G., Heshmati J., et al. 2021 Systematic review, meta-analysis
Jorat M. V., Tabrizi R., et al. 2019 Systematic review, meta-analysis
Alimohammadi M., Rahimi A., et al. 2021 Systematic review, meta-analysis
Health Canada, 2017 Monograph
Schmitt B., Vicenzi M., et al. 2015 Randomized crossover trial
Jahangard, L., Yasrebifar, F., et al. 2019 Double-blind parallel RCT
Fallah, M., Askari, G., et al. 2019 Double-blind parallel RCT
Gholami, M., Zarei, P., et al. 2018 Double-blind parallel RCT
Zarei, P., Rezvanfar, M. R., et al. 2018 Double-blind parallel RCT
Singh R. B., Fedacko J., et al. 2018 Double-blind parallel RCT
Nattagh-Eshtivani E., Dahri M., et al. 2018 Double blind, placebo
Abdollahzad H., Aghdashi M. A., et al. 2015 Randomized, double-blind
Rodríguez-Carrizalez A. D., Castellanos-González J. A., et al. 2015 Randomized, double-blind
Akbari Fakhrabadi M., Zeinali Ghotrom A., et al. 2015 Randomized, double-blind
Farhangi M. A., Alipour B., et al. 2014 Double-blind parallel RCT
Sanoobar M., Eghtesadi S., et al. 2013 Randomized double-blind
Lee B.-J., Huang Y.-C., et al. 2012 Randomized, placebo-controlled
Moazen M., Mazloom Z., et al. 2015 Single-blind parallel RCT
Richie JP Jr., Nichenametla S., et al. 2014 Randomized, double-blind
Harris CB., Chowanadisai W., et al. 2013 Clinical study, cross-over design
Sinha R., Sinha I., et al. 2017 Randomized, open study
Samiec PS., Drews-Botsch C., et al. 1998 Clinical trial
Al-Turk WA., Stohs SJ., et al. 1987 Clinical trial
Matsubara LS., Machado PE.,1991 Clinical trial
Lang C.A., Naryshkin S., et al. 1992 Clinical trial
Erden-Inal M., Sunal E., et al. 2002 Clinical trial
van Lieshout EM., Peters WH., 1998 Clinical trial
Hupfeld KE., Hyatt HW., et al. 2021 Clinical trial
Venkateshappa C., Harish G., et al. 2012 Clinical trial
Rizvi et al 2007 Clinical trial
Lenton KJ., Therriault H., et al. 2000 Clinical trial
Ramires PR., Ji LL., 2001 Preclinical study
Loguercio C., D'Argenio G., et al. 2003 Preclinical study
Stites T., Storms D., et al. 2006 In vivo, preclinical study
Bauerly K., Harris C., et al. 2011 In vivo, preclinical study
Farooqui MY., Day WW., Zamorano DM., 1987 Preclinical study
Emami A. 2019 Preclinical study
Rebrin I., Kamzalov S., Sohal RS., 2003 Preclinical study
Stohs SJ., Lawson T., Al-Turk WA., 1984 Preclinical study
Nunome K., Miyazaki S., et al. 2008 In vitro, preclinical study
Tao R., Karliner JS., et al. 2007 In vitro, preclinical study
Naito Y., Kumazawa T., et al. 1993 In vitro, preclinical study
Kasahara T., Kato T., 2003 In vitro, preclinical study
Dermatologic health Study Type
Nakano M., Kamimura A., et al. 2015 In vitro, preclinical
Heart & circulatory health Study Type
de Frutos F., Gea A., et al. 2014 Meta-analysis
Fotino, A.D., Thompson-Paul, A.M., et al. 2013 Meta-analysis
Gao L., Mao Q., et al. 2011 Meta-analysis
Mortensen S. A., Rosenfeldt F., et al. 2014 Randomized, double-blind
Mohammadshahi M., Farsi F., et al. 2014 Randomized pilot study
McKinley-Barnard S., Andre T., et al. 2022 Preclinical study
Inflammation & immune response Study Type
Fan L., Feng Y., et al. 2017 Meta-analysis & systematic review
Zhai J., Bo Y., et al. 2017 Meta-analysis & systematic review
Liu H.-T., Huang Y.-C., et al. 2016 Randomized, placebo-controlled
Lee B.-J., Tseng Y.-F., et al. 2013 Randomized, placebo-controlled
Emami A., 2019 Open label, RCT
Díaz-Castro J., Guisado R., et al. 2011 Double-blind RCT
To K., Cao R., et al 2021 Randomized, double-blind
Valdivia A., Ly J., et al. 2017 Randomized, double-blind
Morris D., Guerra C., et al. 2013 Clinical trial
Furukawa T., Meydani SN., Blumberg, J., 1987 Preclinical study
Cai J., Chen Y., et al. 2003 Preclinical study
Liu J.-D., Chi C., et al. 2019 Preclinical study
Wu D., Meydani SN., et el. 1994 In vitro
Zhang Z., Zhang X., et al. 2017 In vitro
Metabolic support Study Type
Dludla P. V., Nyambuya T. M., et al. 2020 Meta-analysis & systematic review
Tabrizi R., Akbari M., et al. 2015 Meta-analysis & systematic review
Zhang J., Xing C., et al. 2021 Network meta-analysis
Bakhshayeshkaram M., Lankarani K. B., et al. 2018 Meta-analysis & systematic review
Stojanović M., Radenković M., 2017 Meta-analysis
Moradi M., Haghighatdoost F., et al. 2016 Meta-analysis
Raygan F., Rezavandi Z., et al. 2015 Double-blind parallel RCT
Honda Y., Kessoku T., et al. 2017 Honda Y., Kessoku T., et al. 2017
Performance & recovery Study Type
Suksomboon N., Poolsup N., et al. 2022 Randomized, double-blind
Hwang P., Morales Marroquín FE., et al. 2018 Randomized, double-blind
Aoi W., Ogaya Y., et al. 2015 Double-blind, cross-over study
Cooke M., Iosia M., et al. 2008 Randomized, double-blind
Kon, M., Tanabe, K., et al. 2008 Randomized, double-blind
Leeuwenburgh C, Ji LL., 1998 Preclinical study
Novelli GP., Falsini S., Bracciotti G., 1991 Preclinical study
Reproductive support Study Type
Alahmar A. T., Calogero A. E., et al. 2020 Case-control study
Killgore J., Smidt C., et al. 1989 In vivo, preclinical study
Steinberg F., Stites TE., et al. 2003 In vitro, preclinical study
05

Delivery directly to your cells

Biological Delivery Mechanism
Receptor Mediated Endocytosis

Mikra utilizes a patented, transferrin-mediated glycoprotein to ensure direct delivery into your cells through your jejunum (the second part of your small intestine).

Liposomal: A Microencapsulated Transfer

Cellular Liposomes (20nm) are formed in our lab with our bioactive compounds and a liposomal:transferrin matrix which allows 100% passage through your digestive tract.

06

Testing, 1-2-3...

Independent Third Party Testing

The safety and efficacy of our products is prioritized above all else. We strive to ensure that
everything we do enhances the benefit to the end user, from our research, to our delivery systems and precise dosing.

Ultra Performance Liquid Chromatography (UPLC)

This test identifies and quantifies each component of our formula to verify you are receiving the exact ingredients and amount we claim on our label.


Inductively Coupled Plasma Mass Spectrometry (ICP-MS)

This cutting edge test is used to measure the presence of trace metals in our compound to ensure we're not negatively impacting your cellular health as we work to reinforce it.


USP 2022

This tests for the presence of mold, mycotoxins and salmonella to certify our delicate formula is free from foreign bacteria.


07

Multi-omics data is key

Clinical Research

At Mikra, we’re focusing on functional genomics – for every product we launch, we look at how it affects you on a cellular level (genomics) by mapping which gene expression pathways are triggered (transcriptomics), positively and negatively. That way, we know that our product is actually affecting you positively at the most microscopic level: your cells.

Our clinical trial roadmap is structured to inform not only our product innovation and iterations, but also the industries of nutraceuticals and science in general. Upon conclusion, all of our data will be open-sourced and accessible to all.

Background

Chronic Fatigue Syndrome/Myalgic encephalomyelitis is a complicated disorder characterized by extreme fatigue that lasts for at least six months and that can't be fully explained by an underlying medical condition. The fatigue worsens with physical or mental activity, but doesn't improve with rest.

Global population affected

> 78 Million People

Primary standard of care

NONE

Economic impact (USA)

Approximately $9.1 Billion ($20,000/person with CFS/ME)

Trial locale

Multisite, Decentralized

Manufacturing
The characteristic of chronic fatigue is not peripheral fatigue such as decreased muscular power or endurance but central fatigue including memory loss, difficulty of concentration or decline of desire, which impairs physical well-being, psychological and social aspects and leads to social isolation.
In Vitro
The characteristic of chronic fatigue is not peripheral fatigue such as decreased muscular power or endurance but central fatigue including memory loss, difficulty of concentration or decline of desire, which impairs physical well-being, psychological and social aspects and leads to social isolation.
Background

Chronic Fatigue Syndrome/Myalgic encephalomyelitis is a complicated disorder characterized by extreme fatigue that lasts for at least six months and that can't be fully explained by an underlying medical condition. The fatigue worsens with physical or mental activity, but doesn't improve with rest.

Global population affected

> 78 Million People

Primary standard of care

NONE

Economic impact (USA)

Approximately $9.1 Billion ($20,000/person with CFS/ME)

Trial locale

Multisite, Decentralized

IND
The characteristic of chronic fatigue is not peripheral fatigue such as decreased muscular power or endurance but central fatigue including memory loss, difficulty of concentration or decline of desire, which impairs physical well-being, psychological and social aspects and leads to social isolation.
Phase 1-3
The characteristic of chronic fatigue is not peripheral fatigue such as decreased muscular power or endurance but central fatigue including memory loss, difficulty of concentration or decline of desire, which impairs physical well-being, psychological and social aspects and leads to social isolation.

Cart

No more products available for purchase

Your cart is currently empty.